Streetbeat News

ALMS

Alumis Inc.

Industry

Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

Open

3.58

Mkt cap

204M

Volume

High

3.88

P/E Ratio

-0.36

52-wk high

13.53

Low

3.26

Div yield

N/A

52-wk low

3.26

Alumis Inc. reported its 2024 financial results and highlighted significant achievements, including promising clinical trial data and a merger agreement with ACELYRIN. The merger aims to create a strong portfolio of therapies and is expected to close in Q2 2025.

Portfolio Pulse from

March 19, 2025 | 8:15 pm

Alumis Inc. reported its 2024 financial results and highlighted recent achievements, including promising clinical data for its TYK2 inhibitors and a merger agreement with ACELYRIN. The merger aims to create a company with a strong late-stage portfolio and is expected to close in Q2 2025.

Portfolio Pulse from

March 19, 2025 | 8:15 pm

ESK-001 showed strong clinical responses and was well tolerated over 52 weeks in a Phase 2 trial for psoriasis, as presented at the AAD 2025 meeting.

Portfolio Pulse from

March 08, 2025 | 2:15 pm

Alumis Inc. and ACELYRIN, INC. have reaffirmed the strategic and financial rationale behind their proposed merger. This announcement highlights the potential benefits and synergies expected from the merger.

Portfolio Pulse from

March 04, 2025 | 2:15 pm

Alumis Inc. will present 52-week Phase 2 data for its psoriasis treatment ESK-001 at the 2025 American Academy of Dermatology meeting. The company also announced that Phase 3 topline data is expected in Q1 2026.

Portfolio Pulse from

February 28, 2025 | 2:30 pm

Alumis Inc. presented additional Phase 1 data on its CNS penetrant TYK2 inhibitor, A-005, at the ACTRIMS Forum 2025, highlighting its potential for treating neuroinflammatory and neurodegenerative diseases.

Portfolio Pulse from

February 27, 2025 | 9:30 pm

Halper Sadeh LLC is investigating the fairness of the merger between Alumis Inc. and ACELYRIN, INC. for Alumis shareholders. Post-merger, Alumis shareholders will own 55% of the combined entity.

Portfolio Pulse from

February 07, 2025 | 3:00 am

Alumis and ACELYRIN are merging to form a late-stage clinical biopharma company focused on developing and commercializing therapies for immune-mediated diseases.

Portfolio Pulse from

February 06, 2025 | 9:30 pm

Alumis Inc. reported its Q3 2024 financial results, highlighting progress in its clinical programs, including Phase 3 trials for ESK-001 in plaque psoriasis and Phase 2b trials for systemic lupus erythematosus.

Portfolio Pulse from

November 13, 2024 | 9:15 pm

Top Wall Street analysts initiated coverage on several companies, including Alumis Inc., Enliven Therapeutics, Intensity Therapeutics, Terns Pharmaceuticals, and Braze. Notably, Alumis received an Outperform rating with a $25 price target, while Braze was rated Neutral with a $30 target.

Portfolio Pulse from Avi Kapoor

October 31, 2024 | 3:37 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.